+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Psychedelic Drugs Market By Drug Type, By Application, By End User: Global Opportunity Analysis and Industry Forecast, 2023-2032

  • PDF Icon

    Report

  • 230 Pages
  • October 2023
  • Region: Global
  • Allied Market Research
  • ID: 5916188
The Psychedelic Drugs Market was valued for $752.30 million in 2022 and is estimated to reach $2,614.10 million by 2032, exhibiting a CAGR of 13.4% from 2023 to 2032.

Psychedelic drugs, also known as hallucinogens, are a class of substances that can profoundly alter an individual's perception, thoughts, and feelings. Psychedelic drugs are renowned for their ability to induce altered states of consciousness, often characterized by vivid sensory experiences, unusual thoughts, and a heightened sense of connection to the world. Some well-known psychedelics include LSD (lysergic acid diethylamide), psilocybin, mescaline, and DMT (dimethyltryptamine). These substances primarily work by affecting the brain's serotonin receptors, which play a crucial role in mood regulation and perception.

The psychedelic drugs market is expected to register significant growth owing to increasing social acceptance toward psychedelics, surge in investment in the research and development of psychedelic drugs, and rise in mental health crisis. The shifting societal attitude toward psychedelics has emerged as a major driver for the psychedelic drugs market in recent years. Psychedelics were previously stigmatized and largely associated with counterculture movements and illegal activities, but psychedelics are now undergoing a significant transformation in public perception. According to 2020 report by Proceedings of the National Academy of Sciences (PNAS), a peer reviewed journal of the National Academy of Sciences (NAS), it was reported that past research suggests that use of psychedelic substances such as Lysergic acid diethylamide (LSD) or psilocybin may have positive effects on mood and feelings of social connectedness.

The scientific validation, coupled with changing cultural norms, has led to a reevaluation of psychedelics as more than just recreational substances. Moreover, high-profile endorsements from influential figures in various fields, including healthcare professionals, entrepreneurs, and even celebrities, have played a pivotal role in reshaping the narrative surrounding psychedelics. As a result, an increasing number of governments and regulatory bodies are revisiting their policies, decriminalizing or legalizing psychedelic substances for medical and even recreational use in some regions. Thus, the rise in social acceptance toward psychedelics is expected to drive the growth of the market.

Furthermore, the psychedelic drugs market has witnessed a remarkable surge in investment in research and development (R&D) activities, emerging as a major driver for growth and transformation of the market. The surge in investment in psychedelic drugs can be attributed to growing recognition within the medical and scientific communities of the therapeutic potential of psychedelics, particularly in the treatment of mental health disorders such as depression, anxiety, and post-traumatic stress disorder.

Promising clinical trials and studies have showcased the efficacy of substances like psilocybin and 3,4-Methylenedioxymethamphetamine, prompting increased interest and funding for further exploration. For instance, in February 2023, Transcend Therapeutics, a biotechnology company that develops medicines to treat neuropsychiatric diseases, including post-traumatic stress disorder (PTSD), announced that it closed its Series A funding round of $40 million. The funding round will enable Transcend to launch multiple clinical trials, including a phase II study, with its next-generation psychoactive compound. Transcend has raised nearly $42 million as of February 2023. Thus the rise in the investment in research and development of psychedelic drugs is expected to significantly contribute in the growth of the psychedelic drugs market.

In addition, the rise in the mental health crisis has emerged as a major driver for the psychedelic drugs market, signaling a paradigm shift in the way society perceives and addresses mental health disorders. In recent years, the global burden of mental health conditions, including depression, anxiety, post-traumatic stress disorder (PTSD), and addiction, has reached unprecedented levels. For instance, according to World Health Organization, a specialized agency of the United Nations responsible for international public health, as of March 2023, an estimated 3.8% of the population experience depression.

Conventional treatments such as antidepressants and therapy have not always been effective for everyone, leading to a growing demand for alternative approaches. Psychedelic substances, including psilocybin (found in magic mushrooms) and 3,4-Methylenedioxymethamphetamine (commonly known as ecstasy), have garnered significant attention for their potential to offer breakthrough therapies. According to 2023 report by National Library of Medicine, world’s largest biomedical library and a leader in research in computational health informatics, some types of psychedelic drugs, such as psilocybin and 3,4-Methylenedioxymethamphetamine (ecstasy), have shown promise as therapies for treatment-resistant depression and post-traumatic stress disorder.

Thus, the rise in mental health crisis and emergence of psychedelic drugs as promising treatment for depression, anxiety, and post-traumatic stress disorder are expected to drive the growth of the psychedelic drugs market. However, safety concerns represent a significant restraint on the growth of the psychedelic drugs market. While there is a growing body of research suggesting the therapeutic potential of psychedelics, there are also inherent risks associated with their use. One of the primary concerns is the potential for adverse psychological reactions, which can include intense anxiety, paranoia, or even hallucinations that may lead to dangerous behavior.

Moreover, the use of psychedelics in unsupervised or recreational settings can significantly increase the risk of harm, as individuals may not be adequately prepared or have the necessary support to navigate the often intense and unpredictable experiences induced by these substances. The psychedelic drugs market is segmented on the basis of drug type, application, end user, and region. By drug type, the market is categorized into ketamine, psilocybin, and other drug types.

As per application, the market is categorized into mental health, abuse disorders, and other applications. On the basis of end user, the market is categorized into hospitals, mental health center, and other. Region-wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, and rest of LAMEA).

Major key players that operate in the global psychedelic drugs market are Johnson & Johnson, Numinus, Field Trip Health, Enveric Biosciences, Havn Life, PharmaTher, Psyched Wellness, Ceruvia Lifesciences, Apex Labs, and Braxia Scientific

Key Benefits For Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the psychedelic drugs market analysis from 2022 to 2032 to identify the prevailing psychedelic drugs market opportunities.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the psychedelic drugs market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global psychedelic drugs market trends, key players, market segments, application areas, and market growth strategies.

Additional benefits you will get with this purchase are:

  • Quarterly Update and* (only available with a corporate license, on listed price)
  • 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
  • Free Upcoming Version on the Purchase of Five and Enterprise User License.
  • 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
  • 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
  • Free data Pack on the Five and Enterprise User License. (Excel version of the report)
  • Free Updated report if the report is 6-12 months old or older.
  • 24-hour priority response*
  • Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

  • New Product Development/ Product Matrix of Key Players
  • Additional company profiles with specific to client's interest
  • Additional country or region analysis- market size and forecast
  • Criss-cross segment analysis- market size and forecast
  • Expanded list for Company Profiles
  • Historic market data
  • Key player details (including location, contact details, supplier/vendor network etc. in excel format)
  • SWOT Analysis

Key Market Segments

By Application

  • Mental Health
  • Abuse Disorder
  • Others

By End User

  • Hospitals
  • Mental Health Center
  • Others

By Drug Type

  • Ketamine
  • Psilocybin
  • Others

By Region

  • North America
  • U.S.
  • Canada
  • Mexico
  • Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Rest of Europe
  • Asia-Pacific
  • China
  • Japan
  • Australia
  • Rest of Asia-Pacific
  • LAMEA
  • Brazil
  • South Africa
  • Rest of LAMEA
  • Key Market Players
  • Apex Labs
  • Havn Life
  • Numinus Wellness Inc
  • Field Trip Health
  • PharmaTher
  • Johnson & Johnson (J&J)
  • Ceruvia Lifesciences
  • Psyched Wellness
  • Enveric Biosciences
  • Braxia Scientific

 

Please note:

  • Online Access price format is valid for 60 days access. Printing is not enabled.
  • PDF Single and Enterprise price formats enable printing.

 

Table of Contents

CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research methodology
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO Perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.3. Porter’s five forces analysis
3.4. Market dynamics
CHAPTER 4: PSYCHEDELIC DRUGS MARKET, BY DRUG TYPE
4.1. Overview
4.2. Ketamine
4.3. Psilocybin
4.4. Others
CHAPTER 5: PSYCHEDELIC DRUGS MARKET, BY APPLICATION
5.1. Overview
5.2. Mental Health
5.3. Abuse Disorder
5.4. Others
CHAPTER 6: PSYCHEDELIC DRUGS MARKET, BY END USER
6.1. Overview
6.2. Hospitals
6.3. Mental Health Center
6.4. Others
CHAPTER 7: PSYCHEDELIC DRUGS MARKET, BY REGION
7.1. Overview
7.2. North America
7.3. Europe
7.4. Asia-Pacific
7.5. LAMEA
CHAPTER 8: COMPETITIVE LANDSCAPE
8.1. Introduction
8.2. Top winning strategies
8.3. Product mapping of top 10 player
8.4. Competitive dashboard
8.5. Competitive heatmap
8.6. Top player positioning, 2022
CHAPTER 9: COMPANY PROFILES
9.1. Numinus Wellness Inc
9.2. Enveric Biosciences
9.3. Field Trip Health
9.4. Johnson & Johnson (J&J)
9.5. Havn Life
9.6. PharmaTher
9.7. Psyched Wellness
9.8. Apex Labs
9.9. Ceruvia Lifesciences
9.10. Braxia Scientific
List of Tables
Table 01. Global Psychedelic Drugs Market, by Drug Type, 2022-2032 ($ Million)
Table 02. Psychedelic Drugs Market for Ketamine, by Region, 2022-2032 ($ Million)
Table 03. Psychedelic Drugs Market for Psilocybin, by Region, 2022-2032 ($ Million)
Table 04. Psychedelic Drugs Market for Others, by Region, 2022-2032 ($ Million)
Table 05. Global Psychedelic Drugs Market, by Application, 2022-2032 ($ Million)
Table 06. Psychedelic Drugs Market for Mental Health, by Region, 2022-2032 ($ Million)
Table 07. Psychedelic Drugs Market for Abuse Disorder, by Region, 2022-2032 ($ Million)
Table 08. Psychedelic Drugs Market for Others, by Region, 2022-2032 ($ Million)
Table 09. Global Psychedelic Drugs Market, by End-user, 2022-2032 ($ Million)
Table 10. Psychedelic Drugs Market for Hospitals, by Region, 2022-2032 ($ Million)
Table 11. Psychedelic Drugs Market for Mental Health Center, by Region, 2022-2032 ($ Million)
Table 12. Psychedelic Drugs Market for Others, by Region, 2022-2032 ($ Million)
Table 13. Psychedelic Drugs Market, by Region, 2022-2032 ($ Million)
Table 14. North America Psychedelic Drugs Market, by Drug Type, 2022-2032 ($ Million)
Table 15. North America Psychedelic Drugs Market, by Application, 2022-2032 ($ Million)
Table 16. North America Psychedelic Drugs Market, by End-user, 2022-2032 ($ Million)
Table 17. North America Psychedelic Drugs Market, by Country, 2022-2032 ($ Million)
Table 18. U.S. Psychedelic Drugs Market, by Drug Type, 2022-2032 ($ Million)
Table 19. U.S. Psychedelic Drugs Market, by Application, 2022-2032 ($ Million)
Table 20. U.S. Psychedelic Drugs Market, by End-user, 2022-2032 ($ Million)
Table 21. Canada Psychedelic Drugs Market, by Drug Type, 2022-2032 ($ Million)
Table 22. Canada Psychedelic Drugs Market, by Application, 2022-2032 ($ Million)
Table 23. Canada Psychedelic Drugs Market, by End-user, 2022-2032 ($ Million)
Table 24. Mexico Psychedelic Drugs Market, by Drug Type, 2022-2032 ($ Million)
Table 25. Mexico Psychedelic Drugs Market, by Application, 2022-2032 ($ Million)
Table 26. Mexico Psychedelic Drugs Market, by End-user, 2022-2032 ($ Million)
Table 27. Europe Psychedelic Drugs Market, by Drug Type, 2022-2032 ($ Million)
Table 28. Europe Psychedelic Drugs Market, by Application, 2022-2032 ($ Million)
Table 29. Europe Psychedelic Drugs Market, by End-user, 2022-2032 ($ Million)
Table 30. Europe Psychedelic Drugs Market, by Country, 2022-2032 ($ Million)
Table 31. Germany Psychedelic Drugs Market, by Drug Type, 2022-2032 ($ Million)
Table 32. Germany Psychedelic Drugs Market, by Application, 2022-2032 ($ Million)
Table 33. Germany Psychedelic Drugs Market, by End-user, 2022-2032 ($ Million)
Table 34. France Psychedelic Drugs Market, by Drug Type, 2022-2032 ($ Million)
Table 35. France Psychedelic Drugs Market, by Application, 2022-2032 ($ Million)
Table 36. France Psychedelic Drugs Market, by End-user, 2022-2032 ($ Million)
Table 37. UK Psychedelic Drugs Market, by Drug Type, 2022-2032 ($ Million)
Table 38. UK Psychedelic Drugs Market, by Application, 2022-2032 ($ Million)
Table 39. UK Psychedelic Drugs Market, by End-user, 2022-2032 ($ Million)
Table 40. Italy Psychedelic Drugs Market, by Drug Type, 2022-2032 ($ Million)
Table 41. Italy Psychedelic Drugs Market, by Application, 2022-2032 ($ Million)
Table 42. Italy Psychedelic Drugs Market, by End-user, 2022-2032 ($ Million)
Table 43. Spain Psychedelic Drugs Market, by Drug Type, 2022-2032 ($ Million)
Table 44. Spain Psychedelic Drugs Market, by Application, 2022-2032 ($ Million)
Table 45. Spain Psychedelic Drugs Market, by End-user, 2022-2032 ($ Million)
Table 46. Rest of Europe Psychedelic Drugs Market, by Drug Type, 2022-2032 ($ Million)
Table 47. Rest of Europe Psychedelic Drugs Market, by Application, 2022-2032 ($ Million)
Table 48. Rest of Europe Psychedelic Drugs Market, by End-user, 2022-2032 ($ Million)
Table 49. Asia-Pacific Psychedelic Drugs Market, by Drug Type, 2022-2032 ($ Million)
Table 50. Asia-Pacific Psychedelic Drugs Market, by Application, 2022-2032 ($ Million)
Table 51. Asia-Pacific Psychedelic Drugs Market, by End-user, 2022-2032 ($ Million)
Table 52. Asia-Pacific Psychedelic Drugs Market, by Country, 2022-2032 ($ Million)
Table 53. China Psychedelic Drugs Market, by Drug Type, 2022-2032 ($ Million)
Table 54. China Psychedelic Drugs Market, by Application, 2022-2032 ($ Million)
Table 55. China Psychedelic Drugs Market, by End-user, 2022-2032 ($ Million)
Table 56. Japan Psychedelic Drugs Market, by Drug Type, 2022-2032 ($ Million)
Table 57. Japan Psychedelic Drugs Market, by Application, 2022-2032 ($ Million)
Table 58. Japan Psychedelic Drugs Market, by End-user, 2022-2032 ($ Million)
Table 59. Australia Psychedelic Drugs Market, by Drug Type, 2022-2032 ($ Million)
Table 60. Australia Psychedelic Drugs Market, by Application, 2022-2032 ($ Million)
Table 61. Australia Psychedelic Drugs Market, by End-user, 2022-2032 ($ Million)
Table 62. Rest of Asia-Pacific Psychedelic Drugs Market, by Drug Type, 2022-2032 ($ Million)
Table 63. Rest of Asia-Pacific Psychedelic Drugs Market, by Application, 2022-2032 ($ Million)
Table 64. Rest of Asia-Pacific Psychedelic Drugs Market, by End-user, 2022-2032 ($ Million)
Table 65. LAMEA Psychedelic Drugs Market, by Drug Type, 2022-2032 ($ Million)
Table 66. LAMEA Psychedelic Drugs Market, by Application, 2022-2032 ($ Million)
Table 67. LAMEA Psychedelic Drugs Market, by End-user, 2022-2032 ($ Million)
Table 68. LAMEA Psychedelic Drugs Market, by Country, 2022-2032 ($ Million)
Table 69. Brazil Psychedelic Drugs Market, by Drug Type, 2022-2032 ($ Million)
Table 70. Brazil Psychedelic Drugs Market, by Application, 2022-2032 ($ Million)
Table 71. Brazil Psychedelic Drugs Market, by End-user, 2022-2032 ($ Million)
Table 72. South Africa Psychedelic Drugs Market, by Drug Type, 2022-2032 ($ Million)
Table 73. South Africa Psychedelic Drugs Market, by Application, 2022-2032 ($ Million)
Table 74. South Africa Psychedelic Drugs Market, by End-user, 2022-2032 ($ Million)
Table 75. Rest of LAMEA Psychedelic Drugs Market, by Drug Type, 2022-2032 ($ Million)
Table 76. Rest of LAMEA Psychedelic Drugs Market, by Application, 2022-2032 ($ Million)
Table 77. Rest of LAMEA Psychedelic Drugs Market, by End-user, 2022-2032 ($ Million)
Table 78. Numinus Wellness Inc: Key Executives
Table 79. Numinus Wellness Inc: Company Snapshot
Table 80. Numinus Wellness Inc: Product Segments
Table 81. Numinus Wellness Inc: Product Portfolio
Table 82. Enveric Biosciences: Key Executives
Table 83. Enveric Biosciences: Company Snapshot
Table 84. Enveric Biosciences: Product Segments
Table 85. Enveric Biosciences: Product Portfolio
Table 86. Field Trip Health: Key Executives
Table 87. Field Trip Health: Company Snapshot
Table 88. Field Trip Health: Product Segments
Table 89. Field Trip Health: Product Portfolio
Table 90. Johnson & Johnson (J&J): Key Executives
Table 91. Johnson & Johnson (J&J): Company Snapshot
Table 92. Johnson & Johnson (J&J): Product Segments
Table 93. Johnson & Johnson (J&J): Product Portfolio
Table 94. Johnson & Johnson (J&J): Key Stratergies
Table 95. Havn Life: Key Executives
Table 96. Havn Life: Company Snapshot
Table 97. Havn Life: Product Segments
Table 98. Havn Life: Product Portfolio
Table 99. Havn Life: Key Stratergies
Table 100. Pharmather: Key Executives
Table 101. Pharmather: Company Snapshot
Table 102. Pharmather: Product Segments
Table 103. Pharmather: Product Portfolio
Table 104. Pharmather: Key Stratergies
Table 105. Psyched Wellness: Key Executives
Table 106. Psyched Wellness: Company Snapshot
Table 107. Psyched Wellness: Product Segments
Table 108. Psyched Wellness: Product Portfolio
Table 109. Psyched Wellness: Key Stratergies
Table 110. Apex Labs: Key Executives
Table 111. Apex Labs: Company Snapshot
Table 112. Apex Labs: Product Segments
Table 113. Apex Labs: Product Portfolio
Table 114. Ceruvia Lifesciences: Key Executives
Table 115. Ceruvia Lifesciences: Company Snapshot
Table 116. Ceruvia Lifesciences: Product Segments
Table 117. Ceruvia Lifesciences: Product Portfolio
Table 118. Braxia Scientific: Key Executives
Table 119. Braxia Scientific: Company Snapshot
Table 120. Braxia Scientific: Product Segments
Table 121. Braxia Scientific: Product Portfolio
List of Figures
Figure 01. Psychedelic Drugs Market, 2022-2032
Figure 02. Segmentation of Psychedelic Drugs Market, 2022-2032
Figure 03. Top Impacting Factors in Psychedelic Drugs Market (2022 to 2032)
Figure 04. Top Investment Pockets in Psychedelic Drugs Market (2023-2032)
Figure 05. Low Bargaining Power of Suppliers
Figure 06. Low Threat of New Entrants
Figure 07. Low Threat of Substitutes
Figure 08. Low Intensity of Rivalry
Figure 09. Low Bargaining Power of Buyers
Figure 10. Global Psychedelic Drugs Market: Drivers, Restraints and Opportunities
Figure 11. Psychedelic Drugs Market, by Drug Type, 2022 and 2032 (%)
Figure 12. Comparative Share Analysis of Psychedelic Drugs Market for Ketamine, by Country 2022 and 2032 (%)
Figure 13. Comparative Share Analysis of Psychedelic Drugs Market for Psilocybin, by Country 2022 and 2032 (%)
Figure 14. Comparative Share Analysis of Psychedelic Drugs Market for Others, by Country 2022 and 2032 (%)
Figure 15. Psychedelic Drugs Market, by Application, 2022 and 2032 (%)
Figure 16. Comparative Share Analysis of Psychedelic Drugs Market for Mental Health, by Country 2022 and 2032 (%)
Figure 17. Comparative Share Analysis of Psychedelic Drugs Market for Abuse Disorder, by Country 2022 and 2032 (%)
Figure 18. Comparative Share Analysis of Psychedelic Drugs Market for Others, by Country 2022 and 2032 (%)
Figure 19. Psychedelic Drugs Market, by End-user, 2022 and 2032 (%)
Figure 20. Comparative Share Analysis of Psychedelic Drugs Market for Hospitals, by Country 2022 and 2032 (%)
Figure 21. Comparative Share Analysis of Psychedelic Drugs Market for Mental Health Center, by Country 2022 and 2032 (%)
Figure 22. Comparative Share Analysis of Psychedelic Drugs Market for Others, by Country 2022 and 2032 (%)
Figure 23. Psychedelic Drugs Market by Region, 2022 and 2032 (%)
Figure 24. U.S. Psychedelic Drugs Market, 2022-2032 ($ Million)
Figure 25. Canada Psychedelic Drugs Market, 2022-2032 ($ Million)
Figure 26. Mexico Psychedelic Drugs Market, 2022-2032 ($ Million)
Figure 27. Germany Psychedelic Drugs Market, 2022-2032 ($ Million)
Figure 28. France Psychedelic Drugs Market, 2022-2032 ($ Million)
Figure 29. UK Psychedelic Drugs Market, 2022-2032 ($ Million)
Figure 30. Italy Psychedelic Drugs Market, 2022-2032 ($ Million)
Figure 31. Spain Psychedelic Drugs Market, 2022-2032 ($ Million)
Figure 32. Rest of Europe Psychedelic Drugs Market, 2022-2032 ($ Million)
Figure 33. China Psychedelic Drugs Market, 2022-2032 ($ Million)
Figure 34. Japan Psychedelic Drugs Market, 2022-2032 ($ Million)
Figure 35. Australia Psychedelic Drugs Market, 2022-2032 ($ Million)
Figure 36. Rest of Asia-Pacific Psychedelic Drugs Market, 2022-2032 ($ Million)
Figure 37. Brazil Psychedelic Drugs Market, 2022-2032 ($ Million)
Figure 38. South Africa Psychedelic Drugs Market, 2022-2032 ($ Million)
Figure 39. Rest of LAMEA Psychedelic Drugs Market, 2022-2032 ($ Million)
Figure 40. Top Winning Strategies, by Year (2020-2023)
Figure 41. Top Winning Strategies, by Development (2020-2023)
Figure 42. Top Winning Strategies, by Company (2020-2023)
Figure 43. Product Mapping of Top 10 Players
Figure 44. Competitive Dashboard
Figure 45. Competitive Heatmap: Psychedelic Drugs Market
Figure 46. Top Player Positioning, 2022
Figure 47. Numinus Wellness Inc: Net Revenue, 2020-2022 ($ Million)
Figure 48. Numinus Wellness Inc: Revenue Share by Segment, 2022 (%)
Figure 49. Numinus Wellness Inc: Revenue Share by Region, 2022 (%)
Figure 50. Braxia Scientific: Net Revenue, 2021-2022 ($ Million)

Executive Summary

According to the report, the psychedelic drugs market was valued at $0.7 billion in 2022, and is estimated to reach $2.6 billion by 2032, growing at a CAGR of 13.4% from 2023 to 2032.

Psychedelic drugs, also known as hallucinogens, are a class of substances that alter perception, mood, and consciousness. Psychedelics are characterized by their ability to induce altered states of consciousness, which can include vivid visual and auditory hallucinations, a distorted sense of time, and a heightened sense of interconnectedness with the environment and others. Some well-known psychedelic substances include lysergic acid diethylamide, psilocybin, and dimethyltryptamine, 3,4-methyl​enedioxy​methamphetamine among others.

The key factors driving the growth of the psychedelic drugs market are a surge in mental health crisis, rise in the research and development activities in the psychedelics, and rise in social acceptance of psychedelics. The psychedelic drugs market is expected to grow significantly, owing to a surge in the prevalence of mental disorders, rise in investment for research and development of psychedelic substances, and increased social acceptance of psychedelic drugs. The surge in the mental health crisis has emerged as a major driving factor for the growth of the psychedelic drugs market. In recent years, there has been a notable increase in the prevalence of mental health disorders such as depression, anxiety, post-traumatic stress disorder (PTSD), and substance abuse disorders. This escalating crisis has spurred a growing interest in alternative treatment options, particularly those involving psychedelic substances like psilocybin, MDMA, and LSD. Clinical research and trials have shown promising results in using these substances to alleviate symptoms and improve the overall well-being of individuals suffering from various mental health conditions. For instance, according to 2023 report by National Library of Medicine, world’s largest biomedical library and a leader in research in computational health informatics, A series of six phase-II clinical trials studying 3,4-Methyl​enedioxy​methamphetamine (MDMA-AT) for treatment-resistant post-traumatic stress disorder (PTSD) found that 54% of MDMA-AT full-dose participants no longer met the diagnosis of PTSD after two MDMA sessions. Thus, the rise in the prevalence of the mental illness is expected to drive the growth of the market.

In addition, the surge in investment in the research and development of psychedelic drugs has emerged as a major driving factor for the psychedelic drugs market in recent years. This phenomenon can be attributed to a confluence of factors, including changing societal attitudes towards mental health, evolving regulations, and a growing body of scientific evidence suggesting the therapeutic potential of these substances. One of the primary drivers behind this surge is the increasing recognition of the therapeutic potential of psychedelic compounds like psilocybin, MDMA, and LSD in treating various mental health disorders such as depression, anxiety, PTSD, and addiction. Clinical trials and studies have demonstrated promising results, rekindling interest in these substances within the medical and scientific communities. This newfound legitimacy has opened the doors for pharmaceutical companies and startups to invest heavily in researching and developing psychedelic-based treatments. In conclusion, the surge in investment in psychedelic drugs' research and development is transforming the landscape of mental health treatment and is expected to contribute significantly in the growth of the market. In addition, increased social acceptance of psychedelic drugs is expected to positively impact the growth of the market. Over the past few years, there has been a noticeable shift in public perception and attitudes toward psychedelic substances, moving away from the stigmatization and fear that once surrounded psychedelic drugs.

The psychedelic drugs market is segmented on the basis of drug type, application, end user, and region. By drug type, the market is categorized into ketamine, psilocybin, and other drug types. As per application, the market is categorized into mental health, abuse disorders, and other applications. On the basis of end user, the market is categorized into hospitals, mental health center, and other. Region-wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, and rest of LAMEA).

The key players profiled in the study include Johnson & Johnson, Numinus, Field Trip Health, Enveric Biosciences, Havn Life, PharmaTher, Psyched Wellness, Ceruvia Lifesciences, Apex Labs, and Braxia Scientific.

Key Market Insights

On the basis of drug type, the ketamine segment was the highest contributor to the market in 2022. However, psilocybin is expected to register the fastest growth during the forecast period.

On the basis of application, the mental health segment was the highest contributor to the market in 2022. However, abuse disorders are expected to register the fastest growth during the forecast period.

On the basis of end user, the mental health center segment was highest contributor to the market in 2022

On the basis of region, North America generated the largest revenue in 2022. However, Asia-Pacific is anticipated to grow at the highest CAGR during the forecast period.

Companies Mentioned

  • Apex Labs
  • Havn Life
  • Numinus Wellness Inc
  • Field Trip Health
  • PharmaTher
  • Johnson & Johnson (J&J)
  • Ceruvia Lifesciences
  • Psyched Wellness
  • Enveric Biosciences
  • Braxia Scientific

Methodology

The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.

They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.

They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:

  • Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic news articles and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast

Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.

Loading
LOADING...